US biotech BioAge Labs (Nasdaq: BIOA) is expanding its obesity pipeline just months after shelving its lead drug in the ...

Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

EMERYVILLE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic ...

Bioage Labs Inc. is advancing its apelin receptor (APJ) agonist programs for obesity and other indications, and has entered ...

those with adverse LV remodeling, defined as an increase in LV end-diastolic volume greater than 20% (n = 12), and those without adverse remodeling (n = 29). Levels of ELA, AP-17, AP-13, and the ...